Incidence and risk factors for genitourinary infection in individuals with type 2 diabetes using SGLT2 inhibitors
A retrospective study
Keywords:
SGLT2 inhibitors, type 2 diabetes, women, genital infections, urinary infectionsAbstract
Aim: To assess the frequency and risk factors for genitourinary infections in people with type 2 diabetes who are using SGLT2 inhibitors. Study design: A retrospective study. Place and Duration: Jinnah Hospital Lahore from March 2021 to March 2022. Methodology: This study included 57 people with type 2 diabetes who were using SGLT2 inhibitors.The parameters linked to genitourinary infections were observed via the use of multiple logistic regression analyses. This study utilized patients' medical records for observation and analysis. At the beginning of SGLT2 inhibitor therapy, data on the patient's age, gender, height, weight, duration of diabetes, menopausal status, HbA1c, and creatinine levels were collected. Two independent teams of scientists looked through the results of the investigation before concluding the final hypothesis. Results: Genitourinary infection occurred at a rate of 2.37 percent in the first month and 21.78 percent in the second month of the therapy. Genitourinary infections are more likely in individuals with HbA1c values between 7.0 and 8.0% (OR=3.45, p=0.001), 8.0% to 9.0% (OR=8.56, p=0.0001), and 9.0% (OR=11.45, p=0.0001), as well as diabetes medications such as SUR (OR=4.13, p0.001) and insulin (OR=3.81, p0.001).
Downloads
References
Chou R, Cantor AG, Zakher B, Bougatsos C. Screening for HIV in pregnant women: systematic review to update the 2005 US Preventive Services Task Force recommendation. Annals of internal medicine. 2012;157(10):719-28.
Liu X-Y, Zhang N, Chen R, Zhao J-G, Yu P. Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of Diabetes and its Complications. 2015;29(8):1295-303.
Nguyen AL, Green J, Enguidanos S. The relationship between depressive symptoms, diabetes symptoms, and self-management among an urban, low-income Latino population. Journal of Diabetes and its Complications. 2015;29(8):1003-8.
Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgraduate medicine. 2016;128(4):409-17.
Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: a meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2017;19(3):348-55.
Simmering JE, Polgreen LA, Cavanaugh JE, Erickson BA, Suneja M, Polgreen PM. Warmer weather and the risk of urinary tract infections in Women. The Journal of urology. 2021;205(2):500-6.
Kinduryte Schorling O, Clark D, Zwiener I, Kaspers S, Lee J, Iliev H. Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus. Advances in Therapy. 2020;37(8):3463-84.
Fralick M, MacFadden DR. A hypothesis for why sodium glucose co‐transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection. Diabetes, Obesity and Metabolism. 2020;22(5):755-8.
Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. The Australasian medical journal. 2014;7(10):405.
Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List J, editors. Characterisation of urinary tract infections in the setting of pharmacologically induced glucosuria. Diabetologia; 2011: SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA.
List J, Ley S, Ptaszynska A, Johnsson KM, Schmitz BG, Sugg JE, et al., editors. Characterization of genital infections in the setting of pharmacologically induced glucosuria. Diabetes; 2011: AMER DIABETES ASSOC 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA.
McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care. 2020;8(1):e001238.
Caro MKC, Kho SA, Cunanan EC. Incidence and Factors Associated With Genitourinary Infections Among Patients With Type 2 Diabetes Mellitus on SGLT2 Inhibitors: A Single Retrospective Cohort Study. SSRN Electronic Journal. 2022;
GUO M, XU Y. SGLT2 Inhibitors and Stroke Risk in Patients with Type 2 Diabetes—A Systematic Review and Meta-analysis. Diabetes. 2018 May;67(Supplement 1):165-OR.
.15 Hussain M, Hussain A, Rehman H ur, Iqbal J. Prevalence of Genitourinary Infections with Sodium Glucose Co-transporter-2 (sglt2) inhibitors in patients with type 2 diabetes. Pakistan Journal of Medical and Health Sciences. 2021 Oct 30;15(10):2804–7.
MILJKOVIC I, CVEJKUS R, AN P, THYAGARAJAN B, BOUDREAU R, ZMUDA JM. 1442-P: Incidence and Risk Factors for Type 2 Diabetes among the Offspring of Long-Lived Individuals: The Long Life Family Study. Diabetes. 2019 Jun 1;68(Supplement_1).
Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes/Metabolism Research and Reviews. 2017 Jun 16;33(6):e2903.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Bruneck Study. Diabetes [Internet]. 2004 Jun 25;53(7):1782–9. Available from: https://diabetes.diabetesjournals.org/content/diabetes/53/7/1782.full.pdf
Tang H. Cancer Risk Found Associated With Novel Diabetes Medications - SGLT2 Inhibitors. Science Trends. 2018 Feb 12;
Scheen AJ. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism. 2021 Sep;101275.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
